Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 109.06% from the stock’s previous close.
A number of other research firms have also recently commented on CPRX. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. SunTrust Banks, Inc. set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 31st. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.50.
Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $2.87 on Friday. Catalyst Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.24.
COPYRIGHT VIOLATION NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) Stock Rating Reaffirmed by HC Wainwright” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/12/catalyst-pharmaceuticals-inc-cprx-stock-rating-reaffirmed-by-hc-wainwright.html.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany purchased 20,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was acquired at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the insider now directly owns 4,471,026 shares in the company, valued at approximately $11,535,247.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.79% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $144,000. California State Teachers Retirement System purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth about $350,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Catalyst Pharmaceuticals by 1,861.3% during the second quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 59,896 shares during the period. State Street Corp boosted its holdings in shares of Catalyst Pharmaceuticals by 1,971.1% during the second quarter. State Street Corp now owns 938,195 shares of the biopharmaceutical company’s stock worth $2,590,000 after purchasing an additional 892,895 shares during the period. Finally, OxFORD Asset Management LLP boosted its holdings in shares of Catalyst Pharmaceuticals by 46.2% during the second quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 27,228 shares during the period. Institutional investors own 40.11% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.